Trends in Cardiovascular Medicine
Volume 15, Issue 6 , Pages 219-224 , August 2005

Gene Therapy for Cardiac Arrhythmias

  • J. Kevin Donahue

      Affiliations

    • Corresponding Author InformationAddress correspondence to: J. Kevin Donahue, Division of Cardiology, Case Western Reserve University School of Medicine, MetroHealth Campus Rammelkamp-653, 2500 MetroHealth Drive, Cleveland, OH.
    • ,
  • Kan Kikuchi
    • ,
  • Tetsuo Sasano

References 

  1. American Heart Association. Heart disease and stroke statistics—2005 update. Dallas, TX: Author; 2004;
  2. Bauer A, McDonald A, Donahue J. Pathophysiological findings in a model of atrial fibrillation and severe congestive heart failure. Cardiovasc Res. 2004;61:764–770
  3. Bauer A, McDonald AD, Nasir K, et al. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation. 2004;110:3115–3120
  4. Beck C, Uramoto H, Boren J, Akyurek L. Tissue-specific targeting for cardiovascular gene transfer: Potential vectors and future challenges. Curr Gene Ther. 2004;4:457–467
  5. Calkins H, Yong P, Miller J, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: Final results of a prospective, multicenter clinical trial. Circulation. 1999;99:262–270
  6. Donahue J, Kikkawa K, Johns D, et al. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci U S A. 1997;94:4664–4668
  7. Donahue J, Kikkawa K, Thomas AD, et al. Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Ther. 1998;5:630–634
  8. Donahue J, Heldman A, Fraser H, et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med. 2000;6:1395–1398
  9. Echt D, Liebson P, Mitchell L, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med. 1991;324:781–788
  10. Ennis I, Li R, Murphy A, Nuss H. Dual gene therapy with SERCA1 and Kir 2.1 abbreviates excitation without suppressing contractility. J Clin Invest. 2002;109:393–400
  11. Everts M, Curiel D. Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther. 2004;4:337–346
  12. Guo J, Mitsuiye T, Noma A. The sustained inward current in sino-atrial node cells of guinea pig heart. Pflugers Arch. 1997;433:390–396
  13. High K, Tigges M, Manno C, et al. Human immune responses to AAV-2 capsid may limit duration of expression in liver-directed gene transfer in humans with hemophilia B. Blood. 2004;104:413;(abstract)
  14. Hoppe U, Marban E, Johns D. Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfer of two long QT disease genes, HERG and KCNE1. Proc Natl Acad Sci U S A. 2001;98:5335–5340
  15. Ikeda Y, Gu Y, Iwanaga Y, et al. Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer. Circulation. 2002;105:502–508
  16. Jais P, Haissaguerre M, Shah D, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation. 1997;95:572–576
  17. Janvier N, Boyett M. The role of Na–Ca exchange current in the cardiac action potential. Cardiovasc Res. 1996;32:69–84
  18. Johns D, Nuss B, Chiamnovimonvat N, et al. Adenovirus-mediated expression of a voltage-gated potassium channel in vitro (rat cardiac myocytes) and in vivo (rat liver). J Clin Invest. 1995;96:1152–1158
  19. Johns D, Nuss H, Marban E. Suppression of neuronal and cardiac transient outward currents by viral gene transfer of dominant-negative Kv4.2 constructs. J Biol Chem. 1997;272:31598–31603
  20. Kass-Eisler A, Falck-Pedersen E, Alvira M, et al. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci U S A. 1993;90:11498–11502
  21. Kikuchi K, McDonald AD, Sasano T, Donahue JK. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation. 2005;111:264–270
  22. Knight B, Weiss R, Bahu M, et al. Cost comparison of radiofrequency modification and ablation of the atrioventricular junction in patients with chronic atrial fibrillation. Circulation. 1997;96:1532–1536
  23. Kodirov S, Brunner M, Busconi L, Koren G. Long-term restitution of 4-aminopyridine-sensitive currents in Kv1DN ventricular myocytes using adeno-associated virus-mediated delivery of Kv1.5. FEBS Lett. 2003;550:74–78
  24. Lalli M, Johns D, Janecki M, et al. Suppression of KATP currents by gene transfer of a dominant negative Kir6.2 construct. Pflugers Arch. 1998;436:957–961
  25. MacMahon S, Collins R, Peto R, et al. Effect of prophylactic lidocaine in suspected acute myocardial infarction: An overview of results from the randomized, controlled trials. JAMA. 1988;260:1910–1916
  26. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101:2963–2972
  27. Miake J, Marban E, Nuss H. Biological pacemaker created by gene transfer. Nature. 2002;419:132–133
  28. Miake J, Marban E, Nuss H. Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression. J Clin Invest. 2003;111:1529–1536
  29. Nagata K, Marban E, Lawrence J, Donahue J. Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. J Mol Cell Cardiol. 2001;33:575–580
  30. Nuss HB, Johns D, Kaab S, et al. Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene transfer: A prototype for gene therapy for disorders of cardiac excitability and contractility. Gene Ther. 1996;3:900–912
  31. Nuss B, Marban E, Johns D. Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes. J Clin Invest. 1999;103:889–896
  32. Parsonnet V, Bernstein A, Lindsay B. Pacemaker-implantation complication rates: An analysis of some contributing factors. J Am Coll Cardiol. 1989;13:917–921
  33. Plotnikov A, Sosunov E, Qu J, et al. Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation. 2004;109:r31–r37
  34. Qu J, Plotnikov A, Danilo PJ, et al. Expression and function of a biological pacemaker in canine heart. Circulation. 2003;107:1106–1109
  35. Sanguinetti MC, Curran ME, Spector PS, Keating MT. Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci. 1996;93:2208–2212
  36. Schram G, Pourrier M, Melnyk P, Nattel S. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res. 2002;90:939–950
  37. Tomaselli G, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res. 1999;42:270–283
  38. Waldo A, Camm A, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7–12
  39. Warrington K, Gorbatyuk O, Harrison J, et al. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol. 2004;78:6595–6609
  40. Wei S, Colecraft H, DeMaria C, et al. Ca(2+) channel modulation by recombinant auxiliary beta subunits expressed in young adult heart cells. Circ Res. 2000;86:175–184

PII: S1050-1738(05)00088-5

doi: 10.1016/j.tcm.2005.06.007

Trends in Cardiovascular Medicine
Volume 15, Issue 6 , Pages 219-224 , August 2005

Article Tools

* Image Usage & Resolution